Availability of the preparatory documents for the shareholders’ Extraordinary General Meeting convened the November 28, 2023

Availability of the preparatory documents for the shareholders’ Extraordinary General Meeting convened the November 28, 2023

Paris, France, November 6, 2023 – eureKING (ISIN: FR0014009ON9, Euronext Paris), announces the availability of the preparatory documents for the shareholders’ extraordinary general meeting convened on November 28, 2023 to approve the early dissolution of the Company.

The shareholders’ extraordinary general meeting, called to approve the Company’s early dissolution, will be held on Tuesday November 28, 2023, at 11.00 a.m., 25 rue de Marignan, 75008 Paris.

The meeting notice valid as a convening notice was published in the Bulletin des Annonces Légales Obligatoires (BALO) on October 23, 2023, bulletin number 127. It provides the agenda, the draft resolutions and the terms and conditions for attending and voting at the meeting. The convening notice was published in the Journal d'Annonces Légales (JAL) on October 27, 2023 (no.703958).

The preparatory documents are made available to the shareholders and will be retrievable from November 6, 2023 on the eureKING’s website: Meeting on November 28, 2023 | eureKING.

Media contacts

eureKING

Image Sept

Leslie Jung-Isenwater / Sergio de la Calle / Florence Coupry  eureking@image7.fr

+33 (0)1 53 70 74 70

Disclaimer

On June 6, 2023, J.P. Morgan terminated its association with eureKING and waived any fees and compensation in connection with such association. On the same day, J.P. Morgan also waived its entitlement to the payment of any deferred compensation in connection with its role as underwriter in eureKING's initial public offering. J.P. Morgan has informed eureKING that it is not responsible for any portion hereof. 

About eureKING

Founded in March 2022, eureKING is a French SPAC (Special Purpose Acquisition Company) formed with the aim of acquiring European companies in the field of cutting-edge biomanufacturing, with the ambition of creating a leading bio-CDMO in Europe capable of meeting the growing outsourcing needs of this industry. eureKING has chosen to focus on three highly specialized and strategic segments of the biopharmaceutical industry: the production of biologics, in particular new generations of monoclonal antibodies or complex proteins, the production of cell and gene therapies and the production of live biotherapeutics (with applications in the microbiome). 

With a €150 million capital raising in May 2022, eureKING is led by an international management team of experienced healthcare industry talent, 100% dedicated to the SPAC project and its development strategy. eureKING is supported by a Board of Directors with complementary skills in the pharmaceutical and financial expertise to achieve its goal of developing and promoting the promising biomanufacturing sector in Europe on an international scale. 

eureKING is listed on the Professional Segment (“Compartiment Professionnel”) of Euronext Paris since May 12, 2022.

For more information: www.eureking.com

- 2 -